Integral BioSystems, a drug delivery firm, is rolling out rapid-development, fast-track services tailored for start-up companies, fledgling businesses, and entrepreneurs!
No job is too small or too large for Integral BioSystems to give its undivided attention.”— Shikha BarmanBEDFORD, MA, UNITED STATES, September 6, 2026 /EINPresswire.com/ — Bedford, MA – Sept 5, 2026 – Integral BioSystems LLC, a contract research organization based in the Boston area that focuses on drug delivery, possesses multi-tiered expertise across every stage of Chemistry, Manufacturing and Controls (CMC) drug development for small molecules, proteins, and gene therapies. Since launching in 2009, the company has established credibility by developing numerous drug formulations in ophthalmology, dermatology, intranasal, otic, and injectable areas.
Given the current uncertainty surrounding the availability of startup investment funds that enable groundbreaking research into proof-of-concept clinical testing, Integral BioSystems is now offering fast-track packages to startups and fledgling companies. These packages aim to accelerate the development of analytical methods and formulation compositions, providing additional preclinical confidence in their concepts. We have already assisted and guided many companies toward achieving their development milestones; several of these firms have either completed proof-of-concept clinical trials or are planning them.
Integral BioSystems’ scientists collectively bring decades of experience in designing sustained-release injectables, including microspheres encapsulating DNA, proteins, or small molecules. With over a decade in operation, the company possesses turn-key methods for residual solvent and moisture analysis, along with state-of-the-art equipment for producing spray-dried, lyophilized, or suspension products.
Integral invites all companies operating on a tight budget to discuss their programs. Drawing on more than 30 years of experience across all phases of tissue-targeted, sustained-release pharmaceutical formulation development, the firm’s founder, President and CEO Dr. Shikha P. Barman, along with R&D Head Kevin Ward, are eager to talk about any project, no matter how early-stage. Integral also provides turn-key testing services including particle sizing and stability testing.
Integral is here to help.
ABOUT INTEGRAL BIOSYSTEMS
Integral BioSystems is a specialized drug delivery contract research organization that delivers an integrated, practical approach to formulation development projects for both small molecule and large molecule drug candidates. Through its CMC offerings—encompassing analytical method development, formulation development, process development, scale-up, and technology transfer—the company provides contract services to pharmaceutical firms. Additionally, Integral partners with pharmaceutical companies to co-develop products based on its proprietary delivery systems.
The company has created a wide range of dosage forms. Integral BioSystems employs a translational approach to drug development, tailoring delivery systems to meet the biologically effective goals of each therapy. Dosage forms are customized to achieve sustained release, targeted tissue-focused delivery, or fast-release/instant delivery, depending on the desired product attributes. The company offers rapid proof-of-concept feasibility formulations or development leading to IND submission, including cGLP services.
Dave Karasic, Esq.
Chief Operations Officer
Integral BioSystems LLC
dkarasic@integralbiosystems.com
Dave Karasic
Integral BioSystems, LLC
+1 617-820-8483
email us here
